MX2019007041A - Methods and compositions for treating parkinson's disease. - Google Patents

Methods and compositions for treating parkinson's disease.

Info

Publication number
MX2019007041A
MX2019007041A MX2019007041A MX2019007041A MX2019007041A MX 2019007041 A MX2019007041 A MX 2019007041A MX 2019007041 A MX2019007041 A MX 2019007041A MX 2019007041 A MX2019007041 A MX 2019007041A MX 2019007041 A MX2019007041 A MX 2019007041A
Authority
MX
Mexico
Prior art keywords
disease
compositions
methods
treating parkinson
treating
Prior art date
Application number
MX2019007041A
Other languages
Spanish (es)
Inventor
Matthew Carl Lawyer
Carl Henry Lawyer
Original Assignee
Cove Bio Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cove Bio Llc filed Critical Cove Bio Llc
Publication of MX2019007041A publication Critical patent/MX2019007041A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Provided herein are methods and compositions for treating, mitigating, or preventing Parkinson's disease by administration of an anti-malassezial agent.
MX2019007041A 2016-12-13 2017-12-13 Methods and compositions for treating parkinson's disease. MX2019007041A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433324P 2016-12-13 2016-12-13
US201762504898P 2017-05-11 2017-05-11
PCT/US2017/066218 WO2018112106A1 (en) 2016-12-13 2017-12-13 Methods and compositions for treating parkinson's disease

Publications (1)

Publication Number Publication Date
MX2019007041A true MX2019007041A (en) 2022-09-09

Family

ID=62559231

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007041A MX2019007041A (en) 2016-12-13 2017-12-13 Methods and compositions for treating parkinson's disease.

Country Status (7)

Country Link
EP (1) EP3554496A4 (en)
JP (1) JP2020502269A (en)
CN (1) CN110753543A (en)
AU (1) AU2017376458A1 (en)
CA (1) CA3046501A1 (en)
MX (1) MX2019007041A (en)
WO (1) WO2018112106A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113905715A (en) * 2019-06-28 2022-01-07 宝洁公司 Light enhancement processing method
CN113005086B (en) * 2021-02-01 2022-10-28 中国科学院遗传与发育生物学研究所 Application of epothilone D and Apol8 in regulation and control of neural stem cell directional neuron differentiation
CN115813841B (en) * 2023-01-10 2023-09-05 广东迪美新材料科技有限公司 Anti-dandruff itching-relieving composition, preparation method and application thereof, shampoo and preparation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495538B2 (en) * 1999-06-23 2002-12-17 Zinc Therapeutics, Canada Inc. Zinc ionophores as therapeutic agents
WO2008021970A2 (en) * 2006-08-09 2008-02-21 Reid William K Treatment of motor neuron disease, including certain neurological disorders, motor neuropathies and chronic inflammatory diseases
EP1923041A1 (en) * 2006-10-20 2008-05-21 Symrise GmbH & Co. KG Use of C10-C14 alkane diols for the preparation of a composition for the prophylaxis and/or treatment of Malassezia-induced dandruff, and compositions comprising C10-C14 alkane diols
WO2008124131A1 (en) * 2007-04-05 2008-10-16 The John Hopkins University Antifungal agents as neuroprotectants
WO2009003147A1 (en) * 2007-06-26 2008-12-31 Parkinson's Institute Methods and compositions for the treatment of neurological disorders
US20090062244A1 (en) * 2007-09-04 2009-03-05 Joseph Schwarz Pharmaceutical composition
US20140243350A1 (en) * 2011-07-05 2014-08-28 Contera Pharma Aps Use of serotonin receptor agonists for treatment of movement disorders
EP3220901B1 (en) * 2014-11-20 2020-02-19 VIB vzw Means and methods for treatment of early-onset parkinson's disease

Also Published As

Publication number Publication date
CA3046501A1 (en) 2018-06-21
AU2017376458A1 (en) 2019-06-27
CN110753543A (en) 2020-02-04
EP3554496A4 (en) 2020-05-13
JP2020502269A (en) 2020-01-23
WO2018112106A1 (en) 2018-06-21
EP3554496A1 (en) 2019-10-23
AU2017376458A2 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022005290A (en) Heterocyclic compounds as immunomodulators.
JOP20200152A1 (en) Macrocyclic compounds for treating disease
MX2018011419A (en) Estrogen receptor modulators.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
GB2541571A (en) Pharmaceutical compositions
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2018009325A (en) Compounds and methods of treating rna-mediated diseases.
PH12018502154A1 (en) Methods of treating ocular conditions
CR20220215A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CR20220216A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
MX2022006817A (en) Formulations/compositions comprising a btk inhibitor.
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
MX2019007041A (en) Methods and compositions for treating parkinson's disease.
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2017013879A (en) Compositions comprising anakinra.